(Q82657397)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22112608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22112608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22112608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Nicoletta Colombo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22112608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Serafina Mammoliti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22112608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Mårten Kalling

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22112608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Bengt Tholander

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22112608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Lars Sternas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22112608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Giliane Buzenet

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22112608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Donald Chamberlain

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22112608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

21 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22112608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22112608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

125

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22112608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22112608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

42-47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22112608%20AND%20SRC:MED&resulttype=core&format=json

Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

Biology of vascular endothelial growth factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

Markedly elevated levels of vascular endothelial growth factor in malignant ascites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

VEGF-Trap: a VEGF blocker with potent antitumor effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

Regression of established tumors and metastases by potent vascular endothelial growth factor blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

Malignant ascites: systematic review and guideline for treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

Bevacizumab is active in malignant effusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.11.021

10.1016/J.YGYNO.2011.11.021

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22112608%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference